Recent Finacing
Recent Raise
Stylus Medicine develops in vivo genetic medicines combining sequence-specific recombinases with cell-targeted lipid nanoparticles to deliver multi-kilobase payloads for durable in vivo cell engineering, including in vivo CAR-T.
